Open AccessCA125 Immune Complexes in Ovarian Cancer Patients with Low CA125 Concentrations
Author(s) -
Daniel W. Cramer,
Dennis O’Rourke,
Allison F. Vitonis,
Ursula A. Matulonis,
Daniel A DiJohnson,
Patrick M. Sluss,
Christopher P. Crum,
Brian C.S. Liu
Publication year - 2010
Publication title -
clinical chemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.705
H-Index - 218
eISSN - 1530-8561
pISSN - 0009-9147
DOI - 10.1373/clinchem.2010.153122
Subject(s) - ovarian cancer , immune system , medicine , oncology , immunology , cancer
About 20% of women with ovarian cancer have low concentrations of serum cancer antigen 125 (CA125), and this important tumor marker cannot be used to monitor their disease. The measured concentration for mucin 1 (MUC1), or CA15-3, another tumor marker, can be lowered in breast and ovarian cancer patients when circulating immune complexes (CICs) containing antibodies bound to the free antigen are present. Because CA125 and MUC1 are related members of the mucin family, we sought to determine whether CICs might also exist for CA125 and interfere with its clinical assay.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom